Buyout rumors have been circulating for years surrounding what could be the largest deal in pharma since 2010, and a recent FDA advisory committee nod adds billions to the potential buyout pricetag.
Earlier this week, an FDA advisory committee recommended that BioMarin’s Vimizim drug be approved to treat the rare metabolic disease, Morquio A syndrome. A favorable FDA ruling in early 2014 would add further incentive for Big Pharma suitors to purchase BioMarin at a premium price. According to Bloomberg, Vimizim is projected by analysts to be the company’s best-selling therapy by 2017.
The roles appear to have changed for BioMarin, as the orphan drug maker with a history of buying smaller companies with promising pipelines (Huxley Pharmaceuticals, Zystor Therapeutic, Zacharon Pharmaceuticals) now finds itself on the potential buyout block.
Big names, including Sanofi, GSK and Pfizer have all been mentioned as potential suitors.